Cantourage Group SEXTER:HIGH +0.97%24 Current Ratio is 7.63 as of Jun. 2025, which is 25% below its 10-year median of 10.15. GuruFocus rates XTER:HIGH with a GF Score™ of 24/100. The stock has 4 warning signs investors should review. Among 995 Drug Manufacturers companies, Cantourage Group SE ranks better than 91.86% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Cantourage Group SE's current ratio for the quarter that ended in Jun. 2025 was 7.63.
Cantourage Group SE has a current ratio of 7.63. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Cantourage Group SE's Current Ratio or its related term are showing as below:
XTER:HIGH'
s Current Ratio Range Over the Past 10 Years
Min: 2.24 Med: 10.15 Max: 53.94
Current: 7.63
During the past 5 years, Cantourage Group SE's highest Current Ratio was 53.94. The lowest was 2.24. And the median was 10.15.
XTER:HIGH's Current Ratio is ranked better than 91.86% of 995
companies
in the Drug Manufacturers industry
Industry Median: 2
vs XTER:HIGH: 7.63
Cantourage Group SE (XTER:HIGH) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Cantourage Group SE Current Ratio Related Terms
Cantourage Group SE Current Ratio Historical Data
* Premium members only.
The historical data trend for Cantourage Group SE's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:HIGH vs ZTS, UTHR, VTRS: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cantourage Group SE's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cantourage Group SE Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cantourage Group SE's Current Ratio distribution charts can be found below:
* The bar in red indicates where Cantourage Group SE's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cantourage Group SE (XTER:HIGH) has a Current Ratio of 7.63 as of Jun. 2025. This is 25% below median its historical median of 10.15. Over the past decade, Cantourage Group SE's Current Ratio has ranged from 2.24 to 53.94. According to the industry distribution chart, Cantourage Group SE ranks #81 out of 995 companies in the Drug Manufacturers industry, placing it in the top 8.1%.
Is Cantourage Group SE's Current Ratio too high?
Cantourage Group SE's current Current Ratio of 7.63 is 25% below median its 10-year median of 10.15. Over the past 10 years, this metric has ranged from a low of 2.24 to a high of 53.94. The Drug Manufacturers industry median Current Ratio is 2.00. Cantourage Group SE's value of 7.63 is 281.5% above this industry median. Based on the distribution chart, Cantourage Group SE ranks #81 out of 995 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cantourage Group SE has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Cantourage Group SE's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cantourage Group SE ranks #81 out of 995 companies for Current Ratio. This places Cantourage Group SE in the top 8% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.00. Cantourage Group SE's value of 7.63 is 281.5% above this benchmark. Historically, Cantourage Group SE's own Current Ratio has ranged from 2.24 to 53.94 over the past decade. While the company's 10-year median is 10.15 vs. the industry median of 2.00, Cantourage Group SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cantourage Group SE's current Current Ratio of 7.63 is 281.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cantourage Group SE's current Current Ratio is 7.63, which is 25% below median its own 10-year median of 10.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantourage Group SE stock overvalued right now?
Cantourage Group SE (XTER:HIGH) has a current Current Ratio of 7.63. The current Current Ratio is 7.63, which is 25% below median its 10-year median of 10.15 and 281.5% above the Drug Manufacturers industry median of 2.00. Cantourage Group SE's overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Cantourage Group SE (XTER:HIGH), the current Current Ratio is 7.63 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cantourage Group SE is engaged in the manufacture and wholesale of medicinal preparations based on cannabis and the trade and distribution of other legally permissible cannabis products, medical devices, pharmaceuticals, and accessories. The group offers cannabis flowers, dronabinol, CBD, and extracts of various strains.
24GF Score
Get the complete analysis for XTER:HIGH
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:HIGH has been successfully added to your 
